SRPT — Sarepta Therapeutics Share Price
0.000.00%
Last trade - 00:00- $5.22bn
- $5.00bn
- $1.90bn
- 38
- 45
- 17
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.22 | ||
| PEG Ratio (f) | 0.11 | ||
| EPS Growth (f) | 131.16% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.42 | ||
| Price to Tang. Book | 3.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.74 | ||
| EV to EBITDA | 18.81 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.75% | ||
| Return on Equity | 19.71% | ||
| Operating Margin | 11.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 540.1 | 701.89 | 933.01 | 1,243.34 | 1,901.98 | 3,078.94 | 3,774.57 | 37.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +200.78 | +76.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Directors
- M. Kathleen Behrens NEC (68)
- Douglas Ingram PRE (58)
- Ian Estepan CFO (45)
- William Ciambrone EVP (57)
- Ryan Brown SVP (43)
- Louise Rodino-Klapac CSO (43)
- Stephen Mayo DRC
- Richard Barry IND (62)
- Mary Gray IND (68)
- Claude Nicaise IND (68)
- Hans Wigzell IND (83)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 5th, 2013
- Public Since
- June 4th, 1997
- No. of Shareholders
- 144
- No. of Employees
- 1,372
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 97,032,073
- Address
- 215 1st St Ste 415, CAMBRIDGE, 02142-1213
- Web
- https://www.sarepta.com/
- Phone
- +1 6172744000
- Auditors
- KPMG LLP
Upcoming Events for SRPT
Sarepta Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Sarepta Therapeutics Inc Earnings Release
Similar to SRPT
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Sarepta Therapeutics share price?
As of Today at 23:04 UTC, shares in Sarepta Therapeutics are trading at $53.79. This share price information is delayed by 15 minutes.
How has the Sarepta Therapeutics share price performed this year?
Shares in Sarepta Therapeutics last closed at $53.79 and the price had moved by -54.37% over the past 365 days. In terms of relative price strength the Sarepta Therapeutics share price has underperformed the S&P500 Index by -57.1% over the past year.
What are the analyst and broker recommendations for Sarepta Therapeutics?
The overall consensus recommendation for Sarepta Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sarepta Therapeutics dividend yield?
Sarepta Therapeutics does not currently pay a dividend.
Does Sarepta Therapeutics pay a dividend?
Sarepta Therapeutics does not currently pay a dividend.
When does Sarepta Therapeutics next pay dividends?
Sarepta Therapeutics does not currently pay a dividend.
How do I buy Sarepta Therapeutics shares?
To buy shares in Sarepta Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sarepta Therapeutics?
As of the previous close price of $53.79, shares in Sarepta Therapeutics had a market capitalisation of $5.22bn.
Where are Sarepta Therapeutics shares listed?
Here are the trading details for Sarepta Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SRPT
What kind of share is Sarepta Therapeutics?
Based on an overall assessment of its quality, value and momentum Sarepta Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sarepta Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sarepta Therapeutics is $155.09. That is 188.32% above the last closing price of $53.79.
Analysts covering Sarepta Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $7.03 for the next financial year.
Find out moreWhat is the trend in the Sarepta Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sarepta Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.09%.
As of the last closing price of $53.79, shares in Sarepta Therapeutics were trading -54.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sarepta Therapeutics PE Ratio?
The Sarepta Therapeutics PE ratio based on its reported earnings over the past 12 months is 6.22. The shares last closed at $53.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sarepta Therapeutics?
Sarepta Therapeutics' management team is headed by:
- M. Kathleen Behrens - NEC
- Douglas Ingram - PRE
- Ian Estepan - CFO
- William Ciambrone - EVP
- Ryan Brown - SVP
- Louise Rodino-Klapac - CSO
- Stephen Mayo - DRC
- Richard Barry - IND
- Mary Gray - IND
- Claude Nicaise - IND
- Hans Wigzell - IND